(Total Views: 624)
Posted On: 04/01/2022 10:21:14 AM
Post# of 145248
Repeat: "Our results demonstrate that weekly, self-administered Leronlimab was safe, well-tolerated, and efficacious for long-term virologic suppression and should be included in the arsenal of safe, easily administered, longer-acting antiretroviral treatments for people living with HIV-1."
https://journals.plos.org/plospathogens/artic...V3uGGtXUm8
https://journals.plos.org/plospathogens/artic...V3uGGtXUm8
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)